Valuation : Precigen, Inc.

Market Cap 2.46B 2.12B 1.99B 1.82B 3.41B 233B 3.43B 23.56B 9.17B 119B 9.22B 9.02B 393B P/E 2026 *
31.1x
P/E 2027 * 10.1x
Enterprise Value 2.46B 2.12B 1.99B 1.82B 3.41B 233B 3.43B 23.56B 9.17B 119B 9.22B 9.02B 393B EV / Sales 2026 *
10.5x
EV / Sales 2027 * 5.41x
Free-Float
87.38%
Yield 2026 *
-
Yield 2027 * -
1 day-1.01%
1 week-5.77%
Current month-1.01%
1 month+9.41%
3 months+66.50%
6 months+81.00%
Current year+64.11%
1 week 6.6
Extreme 6.6016
7.46
1 month 6.07
Extreme 6.07
7.72
Current year 3.04
Extreme 3.04
7.72
1 year 2.99
Extreme 2.99
7.72
3 years 0.65
Extreme 0.6513
7.72
5 years 0.65
Extreme 0.6513
7.72
10 years 0.65
Extreme 0.6513
32.9
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/10/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 01/02/2008
Director/Board Member 78 01/02/2008
Director/Board Member 70 28/11/2011
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 A Sell

Director

-185,000 0.0620%
8/25/26 A Exercice

Executive/Senior Manager

237,498 0.0796%
8/25/26 A Exercice

Chief Operating Officer

46,026 0.0154%
Change 5-day change 1-year change 3-year change Capi.($)
-1.01%-5.77%+52.11%+279.01% 2.46B
+0.28%-5.97%+58.34%+108.22% 1,034B
+2.01%-0.71%+53.07%+68.99% 654B
+1.39%-2.18%+23.57%+75.43% 459B
+0.86%-4.67%+34.01%+36.27% 343B
-0.44%+2.67%+29.03%+46.67% 307B
-0.25%-2.27%+0.44%+11.84% 251B
+1.92%-0.93%+52.28%+70.67% 237B
+0.31%-3.08%-17.55%-54.91% 202B
+2.45%+0.77%+32.71%+95.59% 186B
Average +0.93%-3.17%+31.80%+73.78% 367.4B
Weighted average by Cap. +1.39%-3.32%+38.53%+66.81%

Financials

2026 *2027 *
Net sales 233M 201M 189M 172M 324M 22.11B 326M 2.23B 870M 11.25B 875M 856M 37.29B 454M 392M 369M 336M 632M 43.12B 635M 4.36B 1.7B 21.94B 1.71B 1.67B 72.74B
Net income 83.08M 71.67M 67.42M 61.42M 115M 7.89B 116M 797M 310M 4.01B 312M 305M 13.3B 257M 222M 209M 190M 357M 24.4B 359M 2.47B 960M 12.41B 965M 944M 41.16B
Net Debt - -
Logo Precigen, Inc.
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Employees
160
Date Price Change Volume
01/09/26 $6.860 -1.01% 2,806,113
31/08/26 $6.930 -0.29% 4,135,656
28/08/26 $6.950 -3.34% 2,703,251
27/08/26 $7.190 -3.10% 4,977,077
26/08/26 $7.420 +1.92% 7,409,483
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
6.860USD
Average target price
14.50USD
Spread / Average Target
+111.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PGEN Stock